Nuwellis Acquires Rendiatech for Kidney Monitoring Tech
Event summary
- Nuwellis completed the acquisition of Rendiatech on March 17, 2026.
- Rendiatech is an Israeli-based developer of automated kidney function monitoring technology.
- The deal expands Nuwellis' capabilities in cardiorenal care by adding diagnostic monitoring tech.
- Rendiatech's platform enables continuous renal monitoring with real-time data capture.
The big picture
Nuwellis' acquisition of Rendiatech strengthens its position in the cardiorenal continuum by adding automated kidney function monitoring. This move complements its Aquadex SmartFlow System, which focuses on fluid removal in critically ill patients. The deal aligns with broader industry trends toward real-time diagnostic tools and data-driven clinical decision-making.
What we're watching
- Integration Challenges
- How Nuwellis will integrate Rendiatech's technology into its existing portfolio.
- Market Expansion
- Whether the acquisition accelerates Nuwellis' growth in critical care and cardiorenal markets.
- Regulatory Compliance
- The pace at which Nuwellis can navigate regulatory hurdles for new diagnostic tools.
Related topics